Tiverton Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Tiverton Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,446	Closed	-$201K	–	755
2019 Q2	$201K	Hold	6,446	–	–	0.01%	558
2019 Q1	$151K	Hold	6,446	–	–	0.01%	545
2018 Q4	$89K	Sell	6,446 -15,188	-70%	-$192K	0.01%	387
2018 Q3	$216K	Buy	21,634 +13,595	+169%	+$223K	0.01%	320
2018 Q2	$163K	Buy	+8,039	New	+$169K	0.01%	336

Other funds holding EIDX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Tiverton Asset Management's EIDX Position: Q3 2019 in Review

Tiverton Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2019, closing a stake of 6,446 shares — an estimated $201K sold.

Tiverton Asset Management first reported a position in EIDX in Q2 2018 and held it in 5 quarters. The position peaked at $216K in Q3 2018. 79 funds tracked by Wall St. Rank hold EIDX as of Q3 2019.

Tiverton Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Tiverton Asset Management sold 6,446 Eidos Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $201K.
Tiverton Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
Tiverton Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $216K in Q3 2018.
79 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.